Despite recent advances in pharmacological treatment of psychiatric disorders, lithium salts remain frequently used, as they are effective and inexpensive alternatives, especially in the treatment of bipolar disorders. Their use is commonly associated with various endocrine disorders, mainly in thyroid and parathyroid function, and in mineral metabolism. This article aims at reviewing these potential endocrinopathies related to the use of lithium to make health care professionals aware and familiar with these possible complications when they follow up patients using this drug, and to make them able to monitor, identify and institute early and appropriate treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s0004-27302012000300001 | DOI Listing |
Biol Trace Elem Res
January 2025
School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, China.
Cadmium is a heavy metal contaminant known to cause various health issues. However, limited research exists on the serum metabolomic effects of cadmium exposure in children. In this study, we recruited 42 children to analyze their serum metabolomic profiles, along with measuring urinary cadmium and creatinine concentrations, to evaluate the impact of environmental cadmium exposure on serum metabolism.
View Article and Find Full Text PDFJ Pineal Res
January 2025
Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Circadian rhythm disruption (CRD), stemming from sleep disorders and/or shift work, is a risk factor for reproductive dysfunction. CRD has been reported to disturb nocturnal melatonin signaling, which plays a crucial role in female reproduction as a circadian regulator and an antioxidant. The hypothalamic-pituitary-ovarian (HPO) axis regulates female reproduction, with luteinizing hormone (LH) pulse pattern playing a pivotal role in folliculogenesis and steroidogenesis.
View Article and Find Full Text PDFYakugaku Zasshi
January 2025
Department of Endocrine Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.
The placenta, which acts as an interface between fetal and maternal circulations, is an indispensable organ for fetal growth in mammalian pregnancy. It mediates the transportation of nutrients, the exchange of gases such as oxygen and carbon dioxide, and the excretion of waste products between the fetus and mother. The surface of placental villi is covered by two layers of mononuclear undifferentiated cytotrophoblasts (CT) and multinucleated syncytiotrophoblasts (ST).
View Article and Find Full Text PDFFront Oncol
December 2024
Hospital del Mar, Parc de Salut Mar, Barcelona, Spain.
The most frequently used standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer patients consists of a CDK4/6 inhibitor (abemaciclib, ribociclib, or palbociclib) combined with endocrine therapy. Despite CDK4/6 inhibitors being part of routine care in the last few years, new adverse events continue to be reported. Here, we report two cases of palinopsia, a rare neurological visual disturbance that refers to the persistence or recurrence of a visual image after the removal of visual stimuli in patients treated with ribociclib and letrozole.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
January 2025
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), CH-8091 Zurich, Switzerland.
Context: Pheochromocytomas and paragangliomas (PPGLs) are rare endocrine tumors that frequently produce catecholamines. Catecholamine-induced cardiometabolic complications substantially contribute to increased morbidity and mortality in PPGL patients prior to surgical resection.
Objective: To determine whether markers of elevated cardiometabolic risk persist in patients following PPGL resection.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!